Edition:
United Kingdom

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

1.45USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,281
52-wk High
$2.95
52-wk Low
$1.25

Chart for

About

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial... (more)

Overall

Beta: --
Market Cap(Mil.): $70.64
Shares Outstanding(Mil.): 24.36
Dividend: --
Yield (%): --

Financials

  CHMA.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.28 -- --
ROI: -34.47 15.07 14.61
ROE: -35.41 16.60 16.34

BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial

* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL

14 May 2018

BRIEF-Chiasma Inc Files For Mixed Shelf Of Up To $100 Million ‍​

* CHIASMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​ Source text: (https://bit.ly/2DLHB1V) Further company coverage:

22 Mar 2018

BRIEF-Chiasma Q4 Loss Per Share $0.25

* ‍EXPECTS TO HAVE A CASH AND INVESTMENT BALANCE OF AT LEAST $35 MILLION AT END OF 2018​ Source text for Eikon: Further company coverage:

20 Mar 2018

Earnings vs. Estimates